ClinicalTrials.gg
SuspendedNCT07529535Updated Apr 17, 2026

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

A Phase 1 interventional study of ALK-N001 for Injection in Advance Solid Tumors, sponsored by Zhejiang Anglikang Pharmaceutical Co., Ltd.. Suspended at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Zhejiang Anglikang Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Why this study was suspended
Participant recruitment has been stopped because the planned sample size has been reached.

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jun 2025, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multicenter, open-label, dose-escalation plus rollover and cohort expansion Phase I/II clinical trial conducted in patients with advanced solid tumors, including esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma. It aims to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ALK-N001 for injection as monotherapy in the treatment of advanced solid tumors such as esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma.

02

Conditions studied

  • Advance Solid Tumors

Keywords

  • ALK-N001
  • Advanced solid tumors
  • Phase Ia
03

In context

Lead sponsor

Zhejiang Anglikang Pharmaceutical Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects meeting all of the following criteria may be enrolled in this study:

    1. Voluntarily sign the form, understand the study, agree to comply with, and be capable of completing all trial procedures;
    2. Male or female aged 18 years or older;
    3. Unresectable and/or advanced solid tumor confirmed histologically and/or cytologically;
    4. Dose escalation + rollover phase (Phase Ia): Patients with advanced solid tumors who have failed standard treatment, have no available standard treatment, or are intolerant to standard treatment (esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma are prioritized); Cohort expansion phase (Phase Ib/II): Divided into 4 cohorts: ① Esophageal squamous cell carcinoma cohort: Failed at least one line of standard treatment; ② Small cell lung cancer cohort: Failed at least one line of standard treatment; ③ Gastric/gastroesophageal junction adenocarcinoma cohort: Failed at least one line of standard treatment; ④ Other solid tumor cohort (the Sponsor and Investigator will jointly decide whether to initiate Cohort 4 and which indications to enroll based on the safety, pharmacokinetics, and efficacy results of the product). Documented radiologically confirmed disease progression after the last anti-tumor therapy;
    5. At least one measurable tumor lesion according to version 1.1 (lesions in previously irradiated or other locally treated areas are generally not considered measurable unless clear progression is observed);
    6. performance status 0-1;
    7. ≥ 3 months;
    8. Adequate organ function meeting the following criteria:

      **Hematologic system (no blood transfusion or hematopoietic growth factor therapy within 14 days)** (ANC) ≥ 1.5 × 10⁹/L count (PLT) ≥ 90 × 10⁹/L (Hb) ≥ 90 g/L **Hepatic function** Total (TBIL) ≤ 1.5 × (ALT) ≤ 3 × ULN;

      • 5 × ULN for patients with liver metastasis or hepatocellular carcinoma Aspartate aminotransferase (AST) ≤ 3 × ULN;
      • 5 × ULN for patients with liver metastasis or hepatocellular carcinoma **Renal function** Creatinine (Cr) ≤ 1.5 × ULN (Ccr) (calculated only if Cr > 1.5 × ULN) ≥ 50 mL/min (calculated using the Cockcroft-Gault formula) **Coagulation function** (APTT) ≤ 1.5 × ULN International normalized ratio (INR) ≤ 1.5 × ULN
    9. Males and females of must agree to use non-pharmacological measures from signing the informed consent form until 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

- Subjects meeting **any** of the following criteria are **ineligible** for enrollment in this study:

  1. Received chemotherapy, radiotherapy (local bone radiotherapy within 2 weeks), biotherapy, macromolecular targeted therapy, immunotherapy, TIL cell therapy, or other anti-tumor treatments within **4 weeks** prior to the first dose of study drug, **except**:

    • Received anti-cancer endocrine therapy (excluding GnRH agonists or antagonists, endocrine replacement therapy, or ), oral fluoropyrimidines, small-molecule targeted drugs, and traditional Chinese medicine with anti-tumor indications within **2 weeks or 5 half-lives** (whichever is longer) prior to the first study drug dose;
    • Received CAR-T, CAR-NK cell therapy, or tumor vaccine therapy within **3 months** prior to study drug administration;
    • Received inactivated viral vaccine within **2 weeks** or non-inactivated viral vaccine within **4 weeks** prior to study drug administration;
    • Received other uninvestigational medicinal products within **4 weeks or 5 half-lives** (whichever is shorter) prior to study drug administration.
  2. Used **strong inducers or strong inhibitors** within 7 days before the first dose, or requires such agents during the study period.
  3. Known **severe ** to any component of the investigational product ( v5.0 grade ≥ 3).
  4. Presence of **central nervous system (CNS) and/or **.

    Subjects with treated may be enrolled if lesions are stable for at least 1 month with no new or enlarging lesions, and therapy has been discontinued for **2 weeks** before the first dose.

  5. Diagnosis of **another within 5 years** prior to enrollment, **except** cured carcinoma in situ of the cervix, squamous cell carcinoma of the skin, basal cell carcinoma, or papillary thyroid carcinoma.
  6. Clinically **uncontrolled third-space fluid effusion** deemed inappropriate by the investigator.
  7. History of severe gastrointestinal disorders including chronic inflammatory bowel disease, intestinal obstruction, or chronic diarrhea.
  8. Severe cardiovascular disease, including but not limited to:

    1. Severe cardiac rhythm or conduction abnormalities requiring clinical intervention (e.g., ventricular arrhythmia, 2nd-3rd degree atrioventricular block);
    2. Acute coronary syndrome, congestive heart failure, stroke, or other cardiovascular events of **grade ≥3** within 6 months prior to first dose;
    3. (NYHA) functional class **≥ II**, (LVEF) \< 50%, or other structural heart disease at high risk as judged by the investigator;
    4. > 450 ms (males), > 470 ms (females) on (calculated by Fridericia formula: QTcF = QT/(RR\^0.33)).

      *Note: If initial screening is abnormal, repeat twice within 48 hours; eligibility determined by the mean of three measurements.*

    5. Clinically uncontrolled hypertension (systolic BP ≥ 150 mmHg and/or diastolic BP ≥ 100 mmHg despite intervention);
    6. Poorly controlled diabetes defined as ** ≥ 8.0%**.
  9. **Active infection** at screening, or systemic anti-infective treatment within 2 weeks before first dose (excluding prophylaxis and urological surgery prophylaxis).
  10. Active (HBsAg positive and HBV-DNA > 500 IU/ml or above the local laboratory lower limit [if local LL > 500 IU/ml]); active (HCV antibody positive, but patients with HCV-RNA below local LL are eligible). Patients receiving prophylactic antiviral therapy **other than interferon** are allowed.

    Active syphilis or **positive screening**.

  11. Severe pulmonary disease (e.g., pulmonary embolism, interstitial lung disease) within **6 months** prior to first dose.
  12. History of deep vein thrombosis or any **severe thromboembolism** within 6 months before first dose (implanted venous port/catheter-related thrombosis, superficial venous thrombosis, or lacunar infarction are **not** considered severe).

    Known familial and/or acquired thrombophilia (hereditary or acquired defects in anticoagulant proteins, coagulation factors, fibrinolytic proteins, or high thrombotic risk due to acquired risk factors).

  13. Active hemorrhagic disease or bleeding history of **grade ≥3** within 4 weeks before first dose; high bleeding risk due to tumor invasion of large arteries.
  14. Toxicity from prior anti-tumor therapy **not recovered to grade ≤1** (per NCI-CTCAE v5.0; exceptions include alopecia or other toxicities deemed safe by the investigator) or the level specified in inclusion criteria.
  15. Receiving thrombolytic or anticoagulant therapy (**excluding prophylactic anticoagulation**).
  16. History of hematopoietic stem cell transplantation or organ transplantation.
  17. History of psychiatric disorders (including epilepsy, dementia, etc.).
  18. History of **substance abuse**, or any medical, psychological, or social condition that may interfere with study participation or outcome assessment.
  19. Female subjects who are **breastfeeding** or have a positive blood/urine pregnancy test during screening.

Any other condition (medical, psychological, geographic, etc.) that prevents compliance with study and follow-up procedures, or any other situation in which the investigator deems the subject **unsuitable** for enrollment.

Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    ALK-N001(7.5 mg/m2)

    Participants will receive ALK-N001 for Injection at a dose of 7.5 mg/m², administered by intravenous infusion over a fixed duration of 1 hours (allowable range: ±10 minutes).

    Drug: ALK-N001 for Injection

  • Experimental
    ALK-N001(15 mg/m2)

    Participants will receive ALK-N001 for Injection at a dose of 15 mg/m², administered by intravenous infusion over a fixed duration of 1 hours (allowable range: ±10 minutes).

    Drug: ALK-N001 for Injection

  • Experimental
    ALK-N001(25 mg/m2)

    Participants will receive ALK-N001 for Injection at a dose of 25 mg/m², administered by intravenous infusion over a fixed duration of 1 hours (allowable range: ±10 minutes).

    Drug: ALK-N001 for Injection

  • Experimental
    ALK-N001 (37.5 mg/m²)

    Participants will receive ALK-N001 for Injection at a dose of 37.5 mg/m², administered by intravenous infusion over a fixed duration of 2 hours (allowable range: ±20 minutes).

    Drug: ALK-N001 for Injection

  • Experimental
    ALK-N001 (50 mg/m²)

    Participants will receive ALK-N001 for Injection at a dose of 50 mg/m², administered by intravenous infusion over a fixed duration of 2 hours (allowable range: ±20 minutes).

    Drug: ALK-N001 for Injection

  • Experimental
    ALK-N001 (62.5 mg/m²)

    Participants will receive ALK-N001 for Injection at a dose of 62.5 mg/m², administered by intravenous infusion over a fixed duration of 2 hours (allowable range: ±20 minutes).

    Drug: ALK-N001 for Injection

Interventions

  • DrugALK-N001 for Injection

    The drug is administered via intravenous infusion at a constant rate . The primary dosing schedule was every 2 weeks (Q2W) in a 28-day cycle, while an every 3 weeks (Q3W) schedule with a 21-day cycle was also explored.

    Also known as: ALK-N001, QHL-1618

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity(DLT)

    The occurrence of DLT, and determine Maximum Tolerated Dose or Recommended Phase 2 Dose.

    Time frame: Through study completion, an average of 2 years

  2. Incidence of Adverse Events (AEs)

    Frequency, severity (graded by NCI CTCAE v6.0), and relationship to study drug of alladverse events (AEs) .

    Time frame: Through study completion, an average of 2 years

  3. Incidence of Serious Adverse Events (SAEs)

    Frequency, severity (graded by NCI CTCAE v6.0), and relationship to study drug of serious adverse events (SAEs).

    Time frame: Through study completion, an average of 2 years

  4. Incidence of AEs Leading to Permanent Treatment Discontinuation

    Frequency of AEs that result in permanent discontinuation of the study drug.

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. Area Under the Curve (AUC) of ALK-N001

    Area under the plasma concentration-time curve for ALK-N001.

    Time frame: Through study completion, an average of 2 years

  2. Maximum Concentration (Cmax) of ALK-N001

    Maximum observed plasma concentration of ALK-N001.

    Time frame: Through study completion, an average of 2 years

  3. Trough Concentration (Ctrough) of ALK-N001

    Trough plasma concentration of ALK-N001.

    Time frame: Through study completion, an average of 2 years

  4. Time to Maximum Concentration (Tmax) of ALK-N001

    Time to reach the maximum plasma concentration of ALK-N001.

    Time frame: Through study completion, an average of 2 years

  5. Clearance (CL) of ALK-N001

    Systemic clearance of ALK-N001.

    Time frame: Through study completion, an average of 2 years

  6. Volume of Distribution (Vd) of ALK-N001

    Volume of distribution of ALK-N001.

    Time frame: Through study completion, an average of 2 years

  7. Mean Residence Time(MRT )

    The average residence time of ALK-N001 in the body.

    Time frame: Through study completion, an average of 2 years

  8. Objective Response Rate (ORR)

    The proportion of evaluable participants achieving a best overall response of Complete Response (CR) or Partial Response (PR).

    Time frame: Through study completion, an average of 2 years

  9. Disease Control Rate (DCR)

    Proportion of evaluable participants with a best overall response of CR, PR, or Stable Disease (SD).

    Time frame: Through study completion, an average of 2 years

  10. Duration of Response (DOR)

    Time from the date of first documented response (CR or PR) to the date of first documented disease progression or death due to any cause.

    Time frame: Through study completion, an average of 2 years

  11. Progression-Free Survival (PFS)

    Time from the date of first dose to the date of first documented disease progression or death due to any cause.

    Time frame: Through study completion, an average of 2 years

  12. Overall Survival (OS)

    Time from the date of first dose to the date of death due to any cause.

    Time frame: Through study completion, an average of 2 years

07

Study locations

2 sites
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • Zhongshan Hospital, Fudan University
    Shanghai, 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 14, 2026
StartActual
Jun 5, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07529535
Lead sponsor
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Jun 5, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion